The Future Gold
Standard in
Newrotex develops innovative silk-based medical
solutions for the nervous system.
Newrotex develops innovative silk-based medical
solutions for the nervous system.
The answer to “Can you repair nerves?” shouldn’t come with caveats. This is why Newrotex is set to disrupt existing approaches to surgical nerve repair. We’re on track to provide an alternative to autografts, the current gold standard in treatment for nerve injuries. A gold standard that requires sacrificing a healthy nerve from another part of the body. With our patented silk-based technology, we’ll deliver an off-the-shelf solution for surgical repair of the nerve. Without the need for long, complicated operations or using expensive donor tissues, Newrotex makes immediate treatment possible for patients who have suffered nerve injuries due to trauma, medical conditions, or surgical treatments.
Annual operations for nerve injuries
Newrotex silk-based nerve conduits address the shortcomings of the solutions currently available.
Most of the world’s 1.5 million annual operations for nerve injuries are treated with autografts requiring a second injury and long surgery times, along with risking donor site morbidity and infection.
All of the major current solutions – autografts, allografts, and hollow tube conduits – are limited when repairing large gaps in nerves. Read Current Approaches for more about these and other shortcomings with current solutions for peripheral nerve repair.
Over the past few decades, the potential biomedical applications of silk have been gaining interest at an exponential rate.
The versatility created by silk’s chemical structure allows for the production of fibres, gels, scaffolds, films, membranes, and powders. Silk has shown to have excellent cell affinity, and being biocompatible, with the ability to tailor biodegradation, silk is an ideal candidate for biomedical applications.
In terms of nerve repair, luminal silk fibres inside the conduit guide regenerating axons, while the bioabsorbable, permeable tube allows nutrients to support nerve regeneration. Furthermore, silk products can be stored at room temperature, thereby removing the need for expensive cold storage and transportation.
Our first product is a silk-based peripheral nerve conduit. Filled with luminal silk fibres, the biocompatible tubular device will be available in a range of lengths and diameters.
These luminal silk fibres are also a distinct product on their own, to be integrated into other hollow tubes available on the market.
The fibres have proven nerve-regenerating properties and animal trials show them to be comparable or superior to autografts. And with a porous tubular biocompatible sheath designed to encourage vascularisation, we provide a new and better approach to treating patients with peripheral nerve injuries.
Newrotex is currently working to advance the Oxford Nerve Conduit towards first-in-human trials. We are also developing collaborations in which our silk platform technology may lead to further improvements in patient care, such as Schwann cell delivery and spinal cord injury repair.
Newrotex are delighted to announce that we have been selected to join the prestigious MedTech Innovator programme. 61 companies were selected from over 1,150 applicants worldwide and the team will kick off in San Francisco next week. CEO Alex Woods “We’re incredibly proud to have been selected for the MedTech Innovator Accelerator programme including the American Society of Plastic Surgeons (ASPS) cohort. It recognises how our regenerative silk technology can help to address the large unmet need for patients to have a robust and effective treatment for nerve injuries”. Read more
Read MoreNewrotex have been awarded an “Outstanding Pitch” award from the Medical Technology Enterprise Consortium (MTEC) following on from the recent MedTech Innovator Road Tour Pitch Event. MTEC are a consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. military personnel and civilians. Newrotex are delighted to receive this recognition of the huge value our technology can offer to early treatment for injured military personnel and CCO Andrew Elphick will be travelling to Richmond, VA to receive the award at MTEC’s 8th Annual Membership Meeting.
Read MoreNewrotex are delighted to announce that we have successfully received an i4i FAST (Funding at the Speed of Translation) Award form the National Institute for Health and Care Research (NIHR). The award, lead by Chief Science Officer Dr Robyn Plowright, will help Newrotex to develop QMS systems to meet regulatory requirements to bring our technology closer to patients.
Read MoreNewrotex were pleased to welcome the Sunday Mirror to our office and lab space and to discuss the important work we are doing to bringing our exciting silk technology closer to patients. The full article is found here: EXCLUSIVE: Spider’s silk could be used to repair human nerve damage in ‘exciting’ new treatment
Read More